Loading...
XMAD
ATRY
Market cap250mUSD
Apr 11, Last price  
2.90EUR
1D
-0.34%
1Q
-15.20%
Jan 2017
95.95%
IPO
72.62%
Name

Atrys Health SA

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
1.09
EPS
—
Div Yield, %
—
Shrs. gr., 5y
31.26%
Rev. gr., 5y
94.22%
Revenues
213m
+5.54%
1,079,2731,018,9041,089,6162,865,8864,560,7566,035,1157,294,14314,836,66731,396,438121,014,000186,994,000201,569,000212,743,000
Net income
-32m
L-30.30%
681,811336,533320,1981,294,79163,03997,15911,98500-23,197,000-23,468,000-45,590,000-31,774,000
CFO
3m
P
000409,89501,316,73301,083,49804,694,000-15,434,000-1,093,0002,997,000

Profile

Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology. The company also provides radiotherapy; and develops therapeutic modalities and diagnostic tools. The company was formerly known as Althia Health, S.L. and changed its name to Atrys Health, S.A. in May 2016. Atrys Health, S.A. was incorporated in 2007 and is headquartered in Madrid, Spain.
URL
https://www.atryshealth.com/es/
IPO date
Jul 22, 2016
Employees
1,928
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
212,743
5.54%
201,569
7.79%
186,994
54.52%
Cost of revenue
67,359
69,789
52,942
Unusual Expense (Income)
NOPBT
145,384
131,780
134,052
NOPBT Margin
68.34%
65.38%
71.69%
Operating Taxes
(1,624)
(2,941)
(1,225)
Tax Rate
NOPAT
147,008
134,721
135,277
Net income
(31,774)
-30.30%
(45,590)
94.26%
(23,468)
1.17%
Dividends
Dividend yield
Proceeds from repurchase of equity
(27)
287
82,478
BB yield
0.01%
-0.10%
-19.50%
Debt
Debt current
14,336
64,311
48,255
Long-term debt
151,789
230,396
267,212
Deferred revenue
1,224
6,662
4,982
Other long-term liabilities
45,659
3,675
6,745
Net debt
142,575
252,452
278,684
Cash flow
Cash from operating activities
2,997
(1,093)
(15,434)
CAPEX
(13,138)
(6,246)
(15,161)
Cash from investing activities
(12,953)
395
(80,586)
Cash from financing activities
(11,508)
8,193
94,773
FCF
170,480
138,915
127,473
Balance
Cash
29,290
42,177
35,844
Long term investments
(5,740)
78
939
Excess cash
12,913
32,177
27,433
Stockholders' equity
(30,871)
(44,820)
315,074
Invested Capital
497,120
599,039
575,155
ROIC
26.82%
22.95%
25.11%
ROCE
29.15%
22.35%
20.70%
EV
Common stock shares outstanding
75,652
75,811
68,204
Price
3.37
-8.17%
3.67
-40.81%
6.20
-38.92%
Market cap
254,949
-8.37%
278,225
-34.20%
422,864
-22.16%
EV
397,667
618,548
1,121,554
EBITDA
174,428
161,453
164,397
EV/EBITDA
2.28
3.83
6.82
Interest
23,496
33,047
4,006
Interest/NOPBT
16.16%
25.08%
2.99%